Adhere to quality control, create superior products |
The Group has the National Engineering Research Center of Antibody Medicine approved by the National Development and Reform Commission. Members of its Academic Committee are all composed of authoritative academicians and well-known experts. We established 4 major R&D bases in Shenyang, Shanghai, Shenzhen and Hangzhou, successfully building the dual platform for biological and chemical drug, covering the whole process of drug development, ranging from basic research, pre-clinical study, and clinical trial to new drug registration and marketing.
The Group has more than 30 listed products, 32 kinds of alternative products, among which 22 serve as National New Drugs. They mainly cover oncology, autoimmune diseases, nephrology, metabolism, dermatology and other related areas of treatment.
The Group has applied for a total of 285 patents for invention. Among them, 90 valid invention patents are granted.
A total of more than 40 state-level major projects have been undertaken, such as “863”, “973” and Projects for “Significant New Drugs Development” of Ministry of Science and Technology of the People´s Republic of China.
Platform for mammalian |
Platform for bacterial cell |
Chemical platform |
Identify and select molecules that have drug efficacy and market potential.
Include process development and control, structural verification, quality standards and stability studies. All of these studies are conducted in accordance with regulatory guidelines to demonstrate that product quality and manufacturing processes meet sufficiently high standards.
Analyze the efficacy and safety of the product under study on animal subjects to guide follow-up clinical trials.
Research
cooperation
clinic
registration